AbbVie’s Stock Plummets Over 12% After Schizophrenia Drug Fails Phase II Trials: An In-Depth Analysis
Pharmaceutical giant AbbVie recently faced a significant setback when one of its experimental drugs for treating schizophrenia failed to show …